Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor
Kathleen Mosure, Michael Sinz(Rutgers, The State University of New Jersey), Thomas Phillip(Bristol-Myers Squibb (United States)), Anand Balakrishnan(Illinois College), Vinod Arora(Bristol-Myers Squibb (Sweden)), Matthew G. Soars(Bristol-Myers Squibb (United States)), Paul M. Scola(Bristol-Myers Squibb (United States)), Fiona McPhee(Bristol-Myers Squibb (United States)), Yue‐Zhong Shu(Bristol-Myers Squibb (United States)), Marc Browning(Bristol-Myers Squibb (United States)), Kenneth S. Santone(Bristol-Myers Squibb (Germany)), Jay O. Knipe(Bristol-Myers Squibb (United States))
Cited by 32
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
|Hepatology|2015|689
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
|The Lancet|2014|343
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
|Chemical Research in Toxicology|1998|312